All posts by: Michael Zand

About Michael Zand

DNA Shed into Blood by Tumors Can Predict Cancer Patients’ Response to Immunotherapy, Says Study – Sci-News.com

Continue reading

2017-10-06 NEWS

Sci-News.com

DNA Shed into Blood by Tumors Can Predict Cancer Patients’ Response to Immunotherapy, Says Study
Sci-News.com
Scientists have shown that mutations present in circulating tumor DNA isolated from the blood predicts the likelihood a patient will respond to checkpoint inhibitor immunotherapies, indicating that a simple blood test could inform clinicians on whether
ctDNA mutational load points to checkpoint inhibition outcomesmedwireNews

all 2 news articles »

Continue reading

2017-10-06 NEWS

WJHL

Gene therapy helps boys with ‘Lorenzo’s Oil’ disease
WJHL
Brian was able to benefit from an experimental treatment while the disease had progressed too far in Brandon to qualify for the gene therapy study. Study results were published Wednesday, Oct. 4 by the New England Journal of Medicine and discussed at

Continue reading

2017-10-06 NEWS

Arcturus Therapeutics, Inc. to Present at the Chardan Gene Therapy Conference
Markets Insider
Chardan’s Inaugural Gene Therapy Conference will feature nearly 30 companies focusing on exciting technologies in gene therapy, including vector-based gene therapy, small RNA and gene editing. The day will consist of fireside chats, individual company …

and more »

Continue reading

2017-10-06 NEWS

Biosensors detect harmful bugs in the lungs of cystic fibrosis patients
Imperial College London
Professor Paul Freemont, co-founder and co-director of The Centre for Synthetic Biology and Innovation at Imperial, said: “The driving force behind this research is to show that these tools work and could be used to detect particular diagnostic markers …

Continue reading

2017-10-06 NEWS

PharmaTimes

Cell and Gene Therapy Catapult in new stemcell deal
PharmaTimes
The Cell and Gene Therapy Catapult (CGT Catapult) will provide its clinical-grade induced Pluripotent Stem Cell (iPSC) line to Seattle based Universal Cells for use in the development of its universal donor cell line. “Induced Pluripotent Stem Cell
CGT Catapult’s iPSC line licensed to Universal Cells for creating universal donor cell lineNews-Medical.net

all 2 news articles »

Continue reading

2017-10-06 NEWS

T cells — burn fat, get fit
Nature.com
… partially preserve effector functions in a hypoglycaemic and hypoxic TME, and that metabolic reprogramming of these cells using a PPARα agonist improves their antitumour functionality and increases efficacy of PD1-targeted immunotherapy in melanoma.

and more »